Paris, October 12, 2022 – 8:00 a.m. CET – Neovacs (Euronext Growth Paris: ALNEV) announces the filing of an international patent application for its new messenger RNA (mRNA) platform in the field of autoimmune and inflammatory diseases , especially around allergies.

mRNAs as a new therapeutic approach in the treatment of autoimmune and inflammatory diseases

Since the pandemic linked to the SARS-CoV-2 virus, mRNA vaccines have been at the heart of the news. This technology has many advantages, such as great versatility and effective and long-lasting responses. Thanks to its expertise in vaccine development, Neovacs has developed a platform for the production of mRNA vaccines.

Very promising preclinical data obtained by the company demonstrate that this new vaccine technology makes it possible to target self-proteins, which are overproduced in certain pathologies. These therapeutic mRNA vaccines can therefore be used in an active immunization strategy to induce a biological response, in order to bring the levels of these targets back to baseline. These results thus open the door to the use of these mRNA vaccines in the context of autoimmune or inflammatory pathologies, such as allergies.

Filing of an international patent application relating to an mRNA vaccine for the treatment of allergies

Neovacs has just filed an international patent application relating to an “mRNA product composed of sequences coding for IL-4 and IL-13”. This filing comes after that of a first application in August 2021 which gives Néovacs a priority on this innovation from this date. Over the past 12 months, the Neovacs teams have been able to reinforce the innovations associated with this program, through scientific (in particular the creation of an R&D team dedicated to mRNA technology) and regulatory investments, to reinforce the relevance of results of this request.

The invention thus protected relates to a therapeutic vaccine and its use for treating pathological effects associated with aberrant IL-4 and IL-13 expression, in particular asthma, food allergies, venom responses and occurrence of anaphylactic shock, atopic dermatitis, pulmonary fibrosis and chronic obstructive pulmonary disease (COPD). This easy-to-produce vaccine would complement the use of Kinoid products, already patented by Neovacs with the Inserm teams of Drs Laurent Reber (INSERM U1291) and Pierre Bruhns (INSERM U1222).

For Hugo Brugière, CEO of Neovacs: “

This new patent filing is the perfect illustration of Neovacs’ capacity for innovation and proof that the synergistic activity of the R&D and Production teams can lead to spectacular advances in the field of autoimmunity. I am very proud to be able to create ever more value for the company and tomorrow for patients.



Neovacs is a French biotechnology company, listed on Euronext Growth since 2010, specializing in therapeutic vaccines targeting the treatment of autoimmune diseases. Its innovative technology called Kinoid®, patented until 2038, and its new mRNA platform, patented until 2042, make it possible to induce a polyclonal immune response, applicable in several indications. The Company has completed promising preclinical work with another therapeutic vaccine, IL-4/IL-13 Kinoid, for the treatment of allergies. The ambition of this new mRNA approach is to accelerate the implementation of products, to enable patients to better tolerate a treatment that would be more effective, well tolerated and very flexible in its administration.

For more information :


Investor Relations

[email protected].fr

01 53 67 36 78


Financial press relations

[email protected]

01 53 67 36 35

This post has the “🔒 Actusnews SECURITY MASTER” service.



– To check this key:

Regulated information:

Inside information:

– Other press releases

Full and original press release in PDF format:

© Copyright Actusnews Wire

Receive the company’s next press releases free of charge by email by subscribing to


Leave a Comment